$CALM

Cal-Maine Foods slides after lower egg prices impact FQ1 results

Cal-Maine Foods (CALM) reported a 42% revenue decline in Q1 due to lower egg prices. Conventional shell egg sales fell 59.5% with a 59.3% drop in average price. The company swung to an operating loss of $82.2M, missing EPS estimates. CEO Sherman Miller cited industry supply imbalance and healthy demand. Shares dropped 6.6% premarket to a 52-week low.

Original reporting
Published Sep 30, 2026, 10:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 11:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cal-Maine Foods slides after lower egg prices impact FQ1 results — source image
Decision brief

The 30-second read

$CALMBearishHigh
01

Why it matters

The earnings miss and revenue drop are likely to trigger short‑term selling pressure, with the stock already down 6.6% pre‑market.

02

Market read

The earnings surprise directly impacts CALM and may influence peer egg producers and broader agribusiness equities.

03

What to watch

Hybrid and cost‑plus pricing contracts may cushion future earnings, and the supply imbalance could reverse later in the year.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Cal‑Maine Foods is the largest U.S. egg producer; its Q1 results reflect a seasonal supply surge and softer pricing.

Company-level read

Ticker impact

$CALMBearishHigh confidence
Context

Q1 earnings miss with 42% revenue decline and EPS -$1.26, driving a 6.6% pre‑market drop.

Expected impact

downward pressure as investors price in the revenue and earnings miss

Evidence & confidence

The company posted a large revenue decline, a swing to an $82.2M loss and missed EPS by $0.49, causing a notable pre‑market decline.

Market effects

Egg producers may see broader pressure as lower shell‑egg prices affect margins across the sector.

U.S. agribusiness and consumer‑goods stocks could face short‑term weakness.

Limited to U.S. food‑production equities; no immediate global macro effect.

Counterpoint

If the company can successfully scale specialty and prepared‑food lines, the stock may rebound on a longer‑term growth narrative.

Key entities

  • Cal‑Maine Foods

    U.S. egg producer reporting Q1 results.

Related articles

$CALMMed

Why Cal-Maine Foods Stock Dipped on Wednesday

Cal-Maine Foods reported Q1 2027 revenue of $539.6M, down 42% YoY, and a GAAP net loss of $58.6M ($1.26 per share). Both figures missed analyst estimates. The company suspended its dividend. Specialty eggs and prepared foods were profitable, but the core conventional egg business posted a loss of over $71M. The stock fell 0.7% on the news.

$LQDAMed

Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more

Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.

$CALMMedAI 8/10

Maine Foods Q1 fiscal 2027 earnings loss

Cal-Maine Foods reported a Q1 2027 net loss of $58.6M, down from a $199.3M profit a year earlier, due to lower egg prices and sales. Net sales fell 41.5% to $539.6M. CEO Sherman Miller cited industry overproduction. Shares dropped 3.4% to $66.22. The company settled a price-rigging allegation earlier this year.

$CALMHighAI 8/10

Cal-Maine (CALM) Stock Trades Down, Here Is Why

Cal-Maine Foods (CALM) reported a Q3 2026 net loss, with net sales down 41.5% YoY to $539.6M, missing estimates. Gross profit fell to $403K, and the company posted a net loss of $58.6M. CEO Sherman Miller attributed results to industry supply imbalance. Shares fell 3%, trading at $66.49.